<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   C-reactive protein in cardiovascular disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       C-reactive protein in cardiovascular disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        C-reactive protein in cardiovascular disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Filippo Crea, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Morrow, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 21, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atherosclerotic cardiovascular disease (ASCVD) is common in the general population and is the most common cause of death in the United States as well as in most developed countries. ASCVD can be subdivided into four major areas:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronary heart disease manifesting as myocardial infarction, angina pectoris, congestive heart failure, and sudden cardiac death
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebrovascular disease manifesting as stroke and transient ischemic attack
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral artery disease manifesting as intermittent claudication and critical limb ischemia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortic atherosclerosis and thoracic or abdominal aortic aneurysm
        </p>
        <p>
        </p>
        <p>
         Inflammation is a known factor in the development of atherosclerosis and subsequent ASCVD events. Ongoing inflammation increases the vulnerability of an atherosclerotic lesion to erosion or rupture. The most extensively studied biomarker of inflammation in ASCVD is C-reactive protein (CRP), an acute phase protein that is produced predominantly by hepatocytes under the influence of cytokines such as interleukin (IL)-6 and tumor necrosis factor-alpha [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants"
         </a>
         .)
        </p>
        <p>
         Despite a lack of specificity for the cause of inflammation, data from numerous epidemiologic studies have shown a significant association between elevated serum or plasma concentrations of CRP and the prevalence of underlying atherosclerosis, the risk of recurrent cardiovascular events among patients with established disease, and the incidence of first cardiovascular events among individuals at risk for atherosclerosis [
         <a href="#rid2">
          2,3
         </a>
         ]. These issues as well as the mechanisms of association with cardiovascular risk will be reviewed here, along with the role of serum CRP in screening for ASCVD risk. The incremental value of CRP beyond traditional risk factors for estimating ASCVD risk in an individual patient is debated and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          POSSIBLE PATHOGENIC ROLE OF CRP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The participation of inflammatory cells and mediators in atherothrombosis is well established [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">
          "Mechanisms of acute coronary syndromes related to atherosclerosis"
         </a>
         .)
        </p>
        <p>
         Whether serum CRP is a nonspecific marker that is increased as part of the acute phase response to inflammatory stimuli or a direct participant in the progression of atherosclerosis and its clinical consequences has been widely discussed, and the evidence has mounted that it is
         <strong>
          not
         </strong>
         causal [
         <a href="#rid5">
          5-7
         </a>
         ]. Early observations suggested that there may be a direct effect of CRP on the development of atherosclerosis [
         <a href="#rid8">
          8-12
         </a>
         ].
        </p>
        <p>
         However, other reports have not supported a direct role of CRP in atherogenesis [
         <a href="#rid3">
          3,10,13-19
         </a>
         ]. Observations from two large (Mendelian randomization) studies suggest that there is not a direct pathogenic role of CRP:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of over 50,000 individuals with and without ischemic ASCVD in whom the levels of high-sensitivity CRP and genotype for four CRP polymorphisms were known, the following findings were noted [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The risk of ischemic heart disease was increased significantly in persons who had serum CRP levels above 3 mg/L, as compared with persons with CRP levels below 1 mg/L (adjusted hazard ratio 1.6, 95% CI 1.2-2.1). (See
         <a class="local">
          'Known stable coronary disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genotype combinations of the four CRP polymorphisms explained a difference in plasma CRP levels of up to 64 percent, resulting in a theoretically predicted increased risk for ischemic heart and cerebrovascular disease of as much as 32 and 25 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Despite the theoretical considerations, none of the genotype combinations were associated with an increased risk of ischemic ASCVD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar findings were noted in a second report of similar design, which used both genome-wide association study and Mendelian randomization techniques [
         <a href="#rid19">
          19
         </a>
         ]. Polymorphisms in five genetic loci strongly associated with CRP levels were identified. However, variants in these CRP loci were not associated with the incidence of coronary heart disease in an analysis of over 28,000 cases and 100,000 controls.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2910949256">
         <span class="h1">
          CRP ASSAYS
         </span>
        </p>
        <p class="headingAnchor" id="H1111935039">
         <span class="h2">
          Test characteristics
         </span>
         <span class="headingEndMark">
          —
         </span>
         CRP can be measured using various assays with different testing characteristics. The assays, however, are broadly separated into traditional assays and high sensitivity CRP (hs-CRP) assays [
         <a href="#rid20">
          20
         </a>
         ]. It is the hs-CRP assays that are used to determine cardiovascular risk.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Traditional assays, developed to aid in the diagnosis of infectious or inflammatory illnesses, have a limit of detection in the range of 3 to 5 mg/L. While generally helpful for the diagnosis of acute infective or inflammatory episodes, this range is above the concentration observed in most apparently healthy individuals, thereby limiting its discriminatory ability to screen for ASCVD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         hs-CRP assays detect concentrations of CRP down to 0.3 mg/L and below [
         <a href="#rid20">
          20,21
         </a>
         ]. These hs-CRP assays are the assays used to assess cardiovascular risk because they are able to quantitate CRP within the range normally seen in asymptomatic patients (&lt;3 mg/L).
        </p>
        <p>
        </p>
        <p>
         While the ideal value that constitutes a high serum hs-CRP (and increased cardiovascular risk) is not clearly defined, ranges articulated by the Centers for Disease Control and Prevention (CDC) and the American Heart Association (AHA) for the use of serum hs-CRP to estimate cardiovascular risk are routinely employed when hs-CRP is measured for this purpose [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-, average-, and high-risk values can be defined as &lt;1, 1 to 3, and &gt;3 mg/L; these values correspond to approximate tertiles in the general population. A value above 10 mg/L should initiate a search for a source of infection or inflammation. This value should then be repeated in two weeks to determine if the elevation is sustained.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Due to the variability of values in an individual over time, the average of two measurements, fasting or nonfasting, and optimally obtained two weeks apart, provides a more stable estimate of cardiovascular risk than a single measurement. (See
         <a class="local">
          'Variability within an individual patient'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The population distribution of hs-CRP may vary by race and ethnicity; however, these differences are likely explained mostly by the prevalence of other risk factors that are associated with hs-CRP [
         <a href="#rid22">
          22,23
         </a>
         ]. As such, the same cutoff values are used across most populations. (See
         <a class="local">
          'Is CRP an independent risk indicator?'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         We incorporate these guidelines into our approach to the use of CRP assays in determining cardiovascular risk. (See
         <a class="local">
          'Our approach to screening with CRP'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1311435769">
         <span class="h2">
          Clinical context
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with any diagnostic test, hs-CRP must be evaluated within the specific clinical context of an individual patient. Of particular interest are comorbid illnesses and medications that may influence CRP levels, such as the use of menopausal hormone therapy in women.
        </p>
        <p class="headingAnchor" id="H338365047">
         <span class="h3">
          Definition of normal
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no standardized CRP value that can be considered normal. However, individuals with values &lt;1 mg/L have been considered to be at lowest risk [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3424132909">
         <span class="h3">
          Variability within an individual patient
         </span>
         <span class="headingEndMark">
          —
         </span>
         hs-CRP values fluctuate in an individual over time [
         <a href="#rid25">
          25,26
         </a>
         ]. These fluctuations are thought to reflect changes in an individual's systemic inflammatory status. As such, if using hs-CRP for cardiovascular risk assessment, the CDC/AHA recommends that the hs-CRP be checked twice to confirm a stable value prior to integrating for risk assessment. The following observations illustrate the magnitude of variability of CRP in adults:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 113 healthy adults, the variability in quarterly serum CRP measurements over one year was similar to that for serum total cholesterol [
         <a href="#rid25">
          25
         </a>
         ]. Between the first and second measurements, 63 percent of hs-CRP values remained in the same quartile, with 90 percent remaining within one quartile of the baseline value.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 259 women aged 18 to 44 years in whom CRP levels were measured up to eight times throughout their menstrual cycles, significant variation of CRP levels was noted throughout the cycle, with CRP levels being highest during menses and lowest during ovulation [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A greater degree of variability was noted in a study in which serial measurements of serum CRP were obtained in 159 patients with stable ischemic heart disease [
         <a href="#rid26">
          26
         </a>
         ]. When patients were stratified into three risk categories (CRP &lt;1, 1 to 3, and &gt;3 mg/L), 40 percent of patients changed risk category between the first and second measurements. Similar fluctuations were noted in interleukin (IL)-6, another inflammatory marker. Significant within-subject variation in hs-CRP levels measured an average of 19 days apart has also been reported among a cohort of 541 apparently healthy persons, with approximately one-third of those with an elevated hs-CRP level (&gt;10 mg/L) reclassified within the normal range on repeat testing [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These observations are consistent with the hypothesis that dynamic systemic inflammatory status may affect coronary risk. They also point to a potential limitation of using serial measurements of CRP to monitor risk status or the response to medical therapies.
        </p>
        <p class="headingAnchor" id="H2953278088">
         <span class="h3">
          Gender differences
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although women have higher levels of CRP than men both in the general population and in patients with stable angina [
         <a href="#rid22">
          22,29
         </a>
         ], elevated serum CRP predicts ASCVD in women  (
         <a class="graphic graphic_figure graphicRef62229" href="/z/d/graphic/62229.html" rel="external">
          figure 1
         </a>
         ) as well as men [
         <a href="#rid30">
          30-36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H845219125">
         <span class="h3">
          Variability within ethnic groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         The interpretation of CRP concentration should be in the context of the ethnicity of the patient, since ethnic background appears to have some influence on baseline CRP levels [
         <a href="#rid37">
          37-39
         </a>
         ]. In a systematic review and meta-analysis of 221,287 individuals from 89 studies, the geometric mean of hs-CRP levels varied significantly depending on ethnic background [
         <a href="#rid37">
          37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2.6 mg/L in Black subjects (n = 18,585)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2.5 mg/L in Hispanic subjects (n = 5049)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2.3 mg/L in South Asian subjects (n = 1053)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2.0 mg/L in non-Hispanic White subjects (n = 104,949)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         1.0 mg/L in East Asian subjects (n = 39,521)
        </p>
        <p>
        </p>
        <p>
         In the Strong Heart Study (a high-risk population of 3277 Native Americans without ASCVD at the time of enrollment but with a 50 percent prevalence of diabetes), the median serum CRP was 3.2 mg/L, higher than that noted in many other populations [
         <a href="#rid38">
          38
         </a>
         ]. After adjusting for traditional risk factors, CRP remained an independent predictor for future ASCVD in most subgroups. However, CRP was not an incremental predictor of risk in the diabetic patient subgroup [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2622254162">
         <span class="h3">
          Specificity
         </span>
         <span class="headingEndMark">
          —
         </span>
         CRP is an acute phase reactant that arises with most inflammatory disorders, thereby reducing its specificity for prediction of ASCVD risk. Thus, elevated values must be considered in the context of other medical conditions. Levels greater than 10 mg/L are likely to be due to systemic inflammatory states such as major infection, trauma, or chronic inflammatory disease [
         <a href="#rid2">
          2,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2892672645">
         <span class="h3">
          Comorbid illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of comorbid illnesses on the reliability of hs-CRP as a risk marker for ASCVD is largely unknown. As examples, inflammatory diseases such as rheumatoid arthritis or systemic lupus erythematosus would be expected to result in higher circulating CRP levels, while cirrhotic liver disease may blunt the production of CRP, leading to lower circulating levels [
         <a href="#rid40">
          40
         </a>
         ]. There are no published studies evaluating the effect of comorbid inflammatory illnesses or liver disease on the discriminatory power of CRP in ASCVD risk stratification.
        </p>
        <p class="headingAnchor" id="H1683541394">
         <span class="h3">
          Renal dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The predictive value of serum CRP applies to patients with end-stage kidney disease on maintenance hemodialysis. (See
         <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">
          "Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among a cohort of 280 patients on chronic hemodialysis, an elevated serum CRP (&gt;8 mg/dL) was seen in nearly one-half (46 percent) of patients and was significantly related to cardiovascular mortality [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among a cohort of 173 patients on chronic hemodialysis, only 58 patients had no history of coronary heart disease (CHD) or CHD equivalent [
         <a href="#rid42">
          42
         </a>
         ]. Over a 27-month follow-up of the patients without CHD or CHD equivalent, mortality was significantly higher among those with CRP ≥3 mg/L compared with CRP &lt;3 mg/L (50 versus 18 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H700526850">
         <span class="h1">
          ASSOCIATION OF CRP WITH CARDIOVASCULAR RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from numerous epidemiologic studies have shown a significant association between elevated serum or plasma concentrations of CRP and the prevalence of underlying atherosclerotic vascular disease, the risk of recurrent cardiovascular events among patients with established disease, and the incidence of first cardiovascular events among individuals not known to have atherosclerosis. When considered alone or in combination with traditional cardiovascular risk factors, elevated CRP levels have been associated with a higher risk of future cardiovascular events [
         <a href="#rid43">
          43-46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H517280927">
         <span class="h2">
          General population without known ASCVD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several large population-based studies evaluating CRP in unselected asymptomatic populations have shown that, among apparently healthy individuals, the baseline level of CRP is associated with the long-term risk of a first myocardial infarction (MI), ischemic stroke, hypertension, peripheral vascular disease, sudden cardiac death, and all-cause mortality  (
         <a class="graphic graphic_figure graphicRef69135" href="/z/d/graphic/69135.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid30">
          30,44,47-54
         </a>
         ]. The correlation between CRP and cardiovascular risk persists after adjustment for age, smoking, lipid levels, blood pressure, and diabetes [
         <a href="#rid20">
          20,24,30-34,47,50,55,56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H523373862">
         <span class="h2">
          Population at high risk for or with known ASCVD
         </span>
        </p>
        <p class="headingAnchor" id="H3479474139">
         <span class="h3">
          CRP after statin treatment and cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In over 31,000 patients from three clinical trials of statin therapy, residual (or “after-treatment”) high-sensitivity CRP had a greater predictive value for cardiovascular events and death than residual (“after-treatment”) LDL-C [
         <a href="#rid57">
          57
         </a>
         ]. Specific findings are described as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual inflammatory risk was associated with incident major adverse cardiovascular events (highest versus lowest high-sensitivity CRP quartile; hazard ratio [HR] 1.31; 95% CI 1.20-1.43), cardiovascular mortality (HR 2.68; 95% CI 2.22-3.23), and all-cause mortality (HR 2.42; 95% CI 2.12-2.77.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Residual LDL-C was not associated with major adverse cardiovascular events but was associated with higher cardiovascular mortality (HR 1.27; 95% CI 1.07-1.50) and all-cause mortality (HR 1.16; 95% CI 1.03-1.32).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H138001468">
         <span class="h3">
          Is CRP an independent risk indicator?
         </span>
         <span class="headingEndMark">
          —
         </span>
         While serum CRP does appear to act as an independent predictor of ASCVD in the general population, the predictive value added to that determined by screening for other coronary risk factors is small [
         <a href="#rid58">
          58
         </a>
         ]. Instead, serum CRP appears to add the greatest predictive value in a subset of patients with intermediate coronary heart disease (CHD) risk as determined by other measures such as the Framingham Risk Score (
         <a class="calc calc_professional" href="/z/d/html/13469.html" rel="external">
          calculator 1
         </a>
         and
         <a class="calc calc_professional" href="/z/d/html/13468.html" rel="external">
          calculator 2
         </a>
         ).
        </p>
        <p>
         Several large studies have demonstrated that serum CRP adds incremental information to global risk assessment using traditional cardiovascular risk factors [
         <a href="#rid24">
          24,59-61
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the largest case-control study, 2459 patients with a history of MI or death from CHD were compared with 3969 controls without a history of CHD within a cohort study of almost 19,000 patients in Iceland [
         <a href="#rid59">
          59
         </a>
         ]. At a mean follow-up of 18 years, when compared with patients with CRP values in the bottom third (&lt;0.78 mg/L), patients with serum CRP in the top third (&gt;2.0 mg/L) had a significantly higher risk of developing CHD (odds ratio [OR] 1.92). However, the magnitude of this effect decreased after adjustment for age, sex, established coronary risk factors, and year of recruitment (OR 1.45). The predictive value of serum CRP in this report remained independent of established risk factors but, in contrast to previous studies, was weaker than that of total cholesterol, smoking history, or systolic blood pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Framingham Offspring Study evaluated CRP levels in 3006 patients without ASCVD and followed these patients for an average of 12 years. When compared with patients with CRP &lt;1 mg/L, and after adjusting for traditional risk factors, patients with CRP &gt;3 mg/L had a significantly higher risk of hard CHD events including MI or CHD-related death (hazard ratio [HR] 1.88, 95% CI 1.18-3.00) as well as a higher risk of total ASCVD (CHD, stroke, transient ischemic attack, claudication; HR 1.58, 95% CI 1.16-2.15) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition, several meta-analyses have found a significant relationship between baseline CRP and subsequent CHD or cardiovascular events [
         <a href="#rid59">
          59,62,63
         </a>
         ]. The largest and most recent of these, a 2012 meta-analysis from the Emerging Risk Factors Collaboration, which evaluated 246,669 persons without prior ASCVD who were pooled from 52 prospective studies, showed that the addition of CRP level to traditional risk factors modestly improved the risk assessment, with a small but significant net reclassification improvement (1.5 percent) [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         In contrast to these findings, other observational studies have suggested only a small or no incremental contribution of serum CRP to traditional risk factors [
         <a href="#rid65">
          65-67
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of over 15,000 individuals from the third National Health and Nutrition Examination Survey (NHANES) in the United States, high serum CRP (&gt;3 mg/L) was rare in the absence of any borderline or abnormal coronary risk factor (4.4 percent in men and 10.3 percent in women) [
         <a href="#rid65">
          65
         </a>
         ]. The likelihood of a high serum CRP was largely attributable to the presence of other risk factors (78 percent in men and 67 percent in women). It was concluded that serum CRP may have limited clinical utility as a screening tool beyond other known cardiovascular risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar findings were noted in the ARIC study, which assessed the association of 19 novel risk markers, including serum CRP, with incident CHD in nearly 16,000 adults followed for up to 15 years [
         <a href="#rid66">
          66
         </a>
         ]. The CRP level did not add significantly to the basic risk factor model (age, sex, total and high-density lipoprotein cholesterol levels, systolic blood pressure, antihypertensive medication use, smoking status, and diabetes) as assessed by the change in area under receiver operating characteristic curves.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Known stable coronary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with known stable coronary disease, a strong positive correlation between CRP measured at baseline and future acute coronary events has been demonstrated in most studies [
         <a href="#rid68">
          68-74
         </a>
         ]. However, results from these studies cannot be directly compared as cut points for CRP levels differed from study to study.
        </p>
        <p>
         In an evaluation of 3771 patients with stable coronary artery disease (CAD) in the PEACE trial, in which patients had high sensitivity CRP (hs-CRP) measured at baseline (with categorization of low, average, or high risk, using cut points of &lt;1, 1 to 3, and &gt;3 mg/L, respectively) and were followed for outcomes of cardiovascular death, MI, or stroke over a mean follow-up of 4.8 years, the following findings were noted [
         <a href="#rid75">
          75
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Across all measured subgroups, including men and women, patients on or off statin therapy, and patients with or without prior coronary revascularization, higher baseline hs-CRP levels were associated with a significantly higher rate of cardiovascular events compared with those with hs-CRP &lt;1 mg/L (hs-CRP 1 to 3 mg/L: adjusted HR 1.4, 95% CI 1.1-1.8; hs-CRP &gt;3 mg/L: adjusted HR 1.5, 95% CI 1.2-2.0).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An elevated hs-CRP was predictive of the development of heart failure (HF) and new diabetes.
        </p>
        <p>
        </p>
        <p>
         In addition to the association with cardiovascular outcomes among patients with stable coronary disease, serum CRP may predict coronary disease progression [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Acute coronary syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The elevated levels of acute phase reactants in patients with an acute coronary syndrome (ACS) appear to be a marker of widespread underlying vascular inflammation and hyperresponsiveness of the inflammatory system to even small stimuli [
         <a href="#rid77">
          77
         </a>
         ]. The association between ACS and elevated serum concentrations of acute phase reactants, such as CRP [
         <a href="#rid71">
          71,78-80
         </a>
         ], serum amyloid A (SAA) [
         <a href="#rid79">
          79,80
         </a>
         ], and interleukin (IL)-6 [
         <a href="#rid81">
          81
         </a>
         ], suggests that chronic inflammation of the coronary arterial wall plays an important role in plaque instability and ACS. However, elevated CRP levels (and other inflammatory markers) are not the result of localized plaque disruption alone. As such, CRP levels should not be used as a diagnostic test to rule in or exclude ACS [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">
          "Mechanisms of acute coronary syndromes related to atherosclerosis"
         </a>
         .)
        </p>
        <p>
         The following observations from several studies are consistent with this hypothesis:
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Prognosis after ACS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased CRP concentrations at admission and prior to hospital discharge are a marker for a worse short- and long-term prognosis in patients with a non-ST elevation ACS [
         <a href="#rid79">
          79,83-88
         </a>
         ]. Some but not all studies have found that serum CRP predicts the risk of a recurrent in-hospital cardiac event [
         <a href="#rid71">
          71
         </a>
         ] or 30-day or long-term mortality after an ST elevation ACS [
         <a href="#rid89">
          89-93
         </a>
         ]. Elevations in serum CRP early after ACS may reflect the extent of and reaction to myocardial injury. Accordingly, if serum CRP is to be used for long-term cardiovascular assessment, the measurement should be delayed for at least four to six weeks after an MI to permit resolution of the acute phase reaction [
         <a href="#rid94">
          94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/77.html" rel="external">
          "Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88759.html" rel="external">
          "Risk factors for adverse outcomes after ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
         In the PROVE IT-TIMI 22 trial, among 4162 patients stabilized after ACS, those with hs-CRP &gt;2.0 mg/L were at a nearly twofold higher risk of developing new or worsening HF during a mean follow-up of 24 months [
         <a href="#rid95">
          95
         </a>
         ]. (See
         <a class="local">
          'Other cardiovascular conditions'
         </a>
         below.)
        </p>
        <p>
         Elevated periprocedural CRP levels are also predictive of a worse outcome after elective or urgent coronary artery stenting, which itself can elicit an inflammatory response [
         <a href="#rid96">
          96-101
         </a>
         ]. As an example, among 2849 patients who received a drug-eluting stent for symptomatic CHD (stable angina or non-ST elevation ACS) and were followed for an average of 2.2 years, patients with an elevated CRP level (defined as ≥3 mg/L) were significantly more likely to experience death, nonfatal MI, stroke, or stent thrombosis (5.6 versus 1.7 percent in those with CRP level &lt;3 mg/L; HR 2.8, 95% CI 1.8-4.3) [
         <a href="#rid101">
          101
         </a>
         ]. Among patients with elevated serum CRP prior to stenting, statins appear to reduce the risk of adverse cardiac events. (See
         <a class="local">
          'Statins'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H697281307">
         <span class="h2">
          Residual inflammation and prognosis after PCI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with CAD who have undergone PCI, secondary prevention of future events is the primary goal of therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The impact of ongoing residual inflammation on future events and mortality was retrospectively assessed in a cohort of 7026 patients who underwent PCI for any indication (53 percent stable angina, 43 percent ACS) at a single center between 2009 and 2016 [
         <a href="#rid102">
          102
         </a>
         ]. Patients had hs-CRP measured at baseline and again at least four weeks later, with hs-CRP &gt;2 mg/L considered high, and were categorized as persistently high risk (hs-CRP &gt;2 mg/L at both time points), increasing risk (low, then high hs-CRP), attenuated risk (high, then low hs-CRP), or persistently low risk (hs-CRP low at both time points). Compared with persistently low-risk patients, patients with persistently high risk had greater than three-fold risk of death after one year (2.6 versus 0.7 percent; adjusted HR 3.2; 95% CI 1.7-6.0) as well as a significantly greater risk of MI (7.5 versus 4.3 percent; adjusted HR 1.6; 95% CI 1.2-2.1).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective review of the prospective randomized EXCEL trial, which compared PCI and CABG for left main coronary stenosis, baseline CRP levels were available in 999 patients [
         <a href="#rid103">
          103
         </a>
         ]. A linear association was seen between increasing CRP levels and the composite primary outcome (death, MI, stroke at three years); patients with CRP ≥10 mg/L had a nearly threefold higher event rate compared to those with CRP &lt;3 mg/L (HR 2.9; 95% CI 1.9-4.5).
        </p>
        <p>
        </p>
        <p>
         While these data raise the potential for therapeutically targeting residual inflammation post-PCI, therapeutic implications have not yet emerged.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other cardiovascular conditions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart failure
         </strong>
         – Data have been limited on the predictive value of serum CRP in patients with HF but generally suggest an association between CRP and outcomes [
         <a href="#rid104">
          104-106
         </a>
         ]. This issue is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3477.html" rel="external">
          "Predictors of survival in heart failure with reduced ejection fraction", section on 'C-reactive protein'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebrovascular disease
         </strong>
         – Similar to its role in atherosclerotic coronary disease, CRP is an independent marker for the development and progression of early carotid atherosclerotic disease (but not the extent of disease) [
         <a href="#rid107">
          107
         </a>
         ], the risk of ischemic stroke [
         <a href="#rid108">
          108,109
         </a>
         ], and prognosis after a stroke [
         <a href="#rid110">
          110-112
         </a>
         ]. In one report, for example, an increase in serum CRP between 12 and 24 hours after symptom onset in patients with a first ischemic stroke predicted an unfavorable outcome [
         <a href="#rid112">
          112
         </a>
         ]. In an observational study of 6430 participants followed for an average of 8.2 years, it was shown that although CRP levels are associated with stroke risk, their use in the assessment of individual stroke risk was limited when other baseline characteristics were taken into account [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac allograft vasculopathy
         </strong>
         – CAD following cardiac transplant is the leading cause of death or retransplantation in cardiac transplant recipients surviving more than six months. Elevated serum CRP appears to be a predictor for transplant vasculopathy and allograft failure [
         <a href="#rid113">
          113,114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3523.html" rel="external">
          "Heart transplantation in adults: Prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3517.html" rel="external">
          "Heart transplantation in adults: Cardiac allograft vasculopathy pathogenesis and risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atrial fibrillation
         </strong>
         – An inflammatory process may play a role in the genesis of atrial fibrillation (AF), as suggested by the high incidence of AF after cardiac surgery. Whether inflammation plays a direct causal role in the development and perpetuation of AF, or if it is a marker for other conditions that predispose to AF remains to be determined. (See
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Inflammation and infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adult congenital heart disease
         </strong>
         — Elevated CRP appears to be a marker of increased risk of death, hospitalization, and worse functional status in adults with congenital heart disease. A prospective cohort study followed 707 adult patients with congenital heart disease (mean age 39 years) with initial clinical assessment between 2012 and 2016 for an average of 27 months [
         <a href="#rid115">
          115
         </a>
         ]. Compared with persons with CRP in the lowest three quartiles, those with CRP in the highest quartile (CRP ≥2.98 mg/L) were at significantly higher risk of death (12 versus 2 percent; adjusted HR 4.2; 95% CI 1.9-9.6) or the combined outcome of death or non-elective hospitalization (31 versus 11 percent; adjusted HR 2.0; 95% CI 1.4-3.0). The mechanistic link(s) between CRP and adverse outcome in this population remain to be determined.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1709222127">
         <span class="h1">
          OUR APPROACH TO SCREENING WITH CRP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated serum or plasma CRP is an independent predictor of atherosclerosis among apparently healthy men and women. Among apparently healthy men, the plasma concentration of CRP predicts the long-term risk of a first myocardial infarction, ischemic stroke, hypertension, peripheral artery disease, sudden cardiac death, and total mortality.
        </p>
        <p class="headingAnchor" id="H1723784404">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of high-sensitivity CRP (hs-CRP) to screen the general population for cardiovascular risk is controversial. While some experts recommend the routine measurement of hs-CRP at the time of cholesterol screening to be used as adjunctive data in the overall assessment of cardiovascular risk, we continue to prioritize the assessment of traditional risk factors and consider hs-CRP primarily for those with intermediate cardiovascular risk as determined using traditional risk factors and one or more of the available risk calculators [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p>
         There are a number of issues that impact upon the utility and cost-effectiveness of this test for routine screening [
         <a href="#rid116">
          116,117
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What is the appropriate range of "normal" concentrations for serum hs-CRP if one were to target therapy? As noted above, the CDC/AHA statement defined high risk as a value above 3 mg/L [
         <a href="#rid2">
          2
         </a>
         ], and many studies evaluating the predictive value of serum CRP compared patients with serum hs-CRP &gt;2 or 3 mg/L to those with values &lt;1 mg/L [
         <a href="#rid30">
          30,34,59,118
         </a>
         ]. However, additional evidence indicates that patients with serum CRP levels above 1 mg/L may be at increased risk compared with those with lower values [
         <a href="#rid118">
          118
         </a>
         ]. Moreover, the "normal" concentration of CRP appears to vary based on ethnicity and, potentially, gender.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         How does the lack of specificity of hs-CRP for ASCVD influence the interpretation of hs-CRP? (See
         <a class="local">
          'Specificity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Should patient management be altered based upon the results of CRP testing? Until the publication of the JUPITER trial, there was no direct evidence that lowering CRP alone would result in a reduction of cardiovascular risk [
         <a href="#rid119">
          119
         </a>
         ]. The JUPITER trial randomly assigned 17,802 healthy men (aged 50 and older) and women (aged 60 and older) with a low density lipoprotein-cholesterol (LDL-C) level below 130 mg/dL (3.4 mmol/L) and a CRP level of at least 2.0 mg/L to treatment with
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         20 mg daily or placebo [
         <a href="#rid120">
          120,121
         </a>
         ]. The trial was stopped early for benefit after a median follow-up of 1.9 years. Because the trial did not include a group with low hs-CRP, it is not possible to know whether the demonstrated benefit of rosuvastatin in the trial was specifically related to underlying vascular inflammation manifest by hs-CRP. However, the primary results of the JUPITER trial suggest a benefit to statin therapy among individuals with an LDL-C level below 130 mg/dL and a CRP level of at least 2.0 mg/L.
        </p>
        <p>
        </p>
        <p>
         CRP is an important marker of inflammation, and its measurement using commercially available hs-CRP assays can aid in ASCVD risk stratification. A large body of available evidence guides the treatment of patients with traditional ASCVD risk factors (ie, hypertension, diabetes mellitus, hyperlipidemia, smoking, obesity) using a combination of lifestyle changes and pharmacotherapies. There is a relative paucity of evidence demonstrating improved ASCVD outcomes following the treatment of an elevated CRP level on top of treating traditional ASCVD risk factors. As such, professional guidelines do not recommend the routine use of hs-CRP to screen for ASCVD risk in the general population. However, screening with hs-CRP appears reasonable in selected populations considered at intermediate risk for ASCVD based on clinical risk factors using one or more of the available risk calculators (ie, 10 to 20 percent at 10 years) in whom treatment with a statin would be expected to reduce the risk of future ASCVD events by 25 percent or more. (See
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p>
         For patients at intermediate risk for ASCVD (ie, 10 to 20 percent risk at 10 years) who do not otherwise qualify for lipid-lowering therapy, we suggest a screening measurement of hs-CRP. We take the following approach to the interpretation of these values:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A value above 10 mg/L should prompt consideration of a source of infection or inflammation, with repeat measurement of hs-CRP in two weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A value of 3 to 10 mg/L should prompt a discussion regarding overall ASCVD risk, lifestyle modifications, management of risk factors for atherosclerosis, and the possibility of risk reduction therapy using a statin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A value of 1 to 3 mg/L should be repeated in two weeks to determine an average value and prompt a discussion regarding lifestyle modifications and the potential for treatment with a statin if the hs-CRP value is 2.0 mg/L or greater.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A value &lt;1 mg/L suggests a lower risk of future ASCVD events.
        </p>
        <p>
        </p>
        <p>
         Different cutoffs may be required for non-white patients in whom risk related to CRP appears variable based on different baseline values of CRP. (See
         <a class="local">
          'Variability within ethnic groups'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3806028092">
         <span class="h2">
          Recommendations of others
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several groups have issued guidelines addressing the role of CRP in screening for coronary heart disease (CHD).
        </p>
        <p>
         In 2018, the United States Preventive Services Task Force (USPSTF) issued recommendations about the use of nontraditional risk factors in the risk assessment for CHD [
         <a href="#rid122">
          122,123
         </a>
         ]. They concluded with regard to hs-CRP testing that there are insufficient data to assess the balance of benefits and harms of using CRP to screen asymptomatic men and women to prevent CHD events.
        </p>
        <p>
         In 2009, the Canadian Cardiovascular Society issued guidelines covering the treatment of dyslipidemia and the prevention of ASCVD [
         <a href="#rid124">
          124
         </a>
         ]. Screening hs-CRP was recommended in men older than 50 years and women older than 60 years who were at intermediate risk by the Framingham Risk Score (FRS; 10 to 20 percent at 10 years) and who would otherwise not qualify for lipid-lowering therapy because of an LDL &lt;3.5 mmol/L (135 mg/dL). These individuals were felt to benefit from screening with hs-CRP due to a potential benefit from statin therapy in those with elevated hs-CRP levels [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
         The 2003 CDC/AHA statement on markers of inflammation and CVD included the following conclusions concerning the use of serum hs-CRP measurements in determining cardiovascular risk that remain pertinent to its clinical application [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If used, hs-CRP should be measured twice, optimally two weeks apart, with the values averaged. Values should be reported in mg/L.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-, intermediate-, and high-risk CRP values were defined as &lt;1, 1 to 3, and &gt;3 mg/L. A value above 10 mg/L should be repeated after an interval of at least two weeks and the patient evaluated for infection or inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients at intermediate risk for ASCVD (10 to 20 percent at 10 years by the FRS), hs-CRP may help direct further evaluation and therapy for primary prevention, at the discretion of the clinician.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          EFFECT OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of drugs used in the treatment of ASCVD and certain dietary modifications reduce serum CRP. It is therefore possible that reduced inflammation contributes to the beneficial effects of these medications.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Statins
         </span>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Effect on CRP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple statins significantly decrease serum CRP in patients with hyperlipidemia; this decrease appears to be independent of reductions in low density lipoprotein-cholesterol (LDL-C) [
         <a href="#rid125">
          125-128
         </a>
         ]. The effect of statins on CRP may be mediated in part by reduced monocyte expression of interleukin (IL)-6 and tumor necrosis factor-alpha [
         <a href="#rid129">
          129,130
         </a>
         ] or by direct suppression of CRP gene transcription [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p>
         Therapy with a statin reduces serum CRP both after an acute coronary syndrome (ACS) [
         <a href="#rid73">
          73,127,132,133
         </a>
         ] and when given for primary prevention [
         <a href="#rid128">
          128,134
         </a>
         ]. The fall in serum CRP is seen as early as 14 days [
         <a href="#rid126">
          126
         </a>
         ]. In a literature review of 13 controlled trials, statins reduced CRP levels by 13 to 50 percent compared with placebo; there was no advantage of one statin over another in five studies making direct comparisons [
         <a href="#rid132">
          132
         </a>
         ]. In phase Z of the A to Z trial, more intensive statin therapy was associated with a modestly greater reduction in CRP [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Reduction in coronary risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         The observations that statin therapy reduces serum CRP and that serum CRP is correlated with cardiovascular risk raise the possibility that the risk reduction with statin therapy may be attributed, at least in part, to anti-inflammatory effects. (See
         <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">
          "Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"
         </a>
         .)
        </p>
        <p>
         Several clinical studies have provided supportive evidence for this concept:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients undergoing percutaneous coronary intervention, observational studies suggest that benefit from statin therapy is principally seen in those with a serum CRP in the upper 25 to 50 percent of the study population [
         <a href="#rid135">
          135,136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the AFCAPS/TexCAPS trial of primary prevention,
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         reduced CRP by almost 15 percent [
         <a href="#rid134">
          134
         </a>
         ]. A significant reduction in coronary events was seen, not only in patients with an elevated total cholesterol-to-HDL cholesterol ratio, but also in those with an elevated serum CRP but no elevation in lipid ratio. Modeling of the AFCAPS/TexCAPS data suggested that 58-year-old men or women with a serum LDL-C concentration below 149 mg/dL (3.9 mmol/L) might benefit from statin therapy if they have a serum CRP concentration ≥1.6 mg/L [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In Phase Z of the A to Z trial, 4497 patients with an ACS were randomly assigned to aggressive statin therapy (
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         40 mg/day for one month, then 80 mg/day) or to delayed conservative statin therapy (placebo for four months, then simvastatin 20 mg/day) [
         <a href="#rid132">
          132
         </a>
         ]. At one month, patients in the aggressive therapy arm had a marked reduction in LDL-C concentration, but
         <strong>
          no
         </strong>
         reduction in the incidence of the primary end point (cardiovascular death, myocardial infarction [MI], readmission for ACS, or stroke). Instead, the benefit seen in Phase Z corresponded to the timing of a reduction in serum CRP seen when the dose of simvastatin was increased from 40 to 80 mg/day. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further assessment of patients in Phase Z of the A to Z trial showed that levels of high sensitivity CRP (hs-CRP) at 30 days and four months after ACS were independently associated with long-term survival. This study also showed that patients treated with more aggressive statin therapy are more likely to achieve lower levels of hs-CRP [
         <a href="#rid138">
          138
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with hs-CRP &gt;3 mg/L at 30 days had significantly higher two-year mortality rates than those with hs-CRP 1 to 3 mg/L or hs-CRP &lt;1 mg/L (6.1 versus 3.7 versus 1.6 percent), and results were similar with hs-CRP measured at four months. Patients allocated to early intensive statin therapy were significantly more likely to achieve hs-CRP levels &lt;1 mg/L at 30 days and four months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PROVE IT-TIMI 22 trial, 4162 patients with an ACS were randomly assigned to
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         80 mg/day or
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         40 mg/day [
         <a href="#rid133">
          133
         </a>
         ]. There were significant reductions in serum CRP by 30 days in both treatment arms. There was only a limited correlation between the achieved levels of CRP and the achieved levels of LDL-C; less than 3 percent of the variance in achieved serum CRP was explained by the variance in achieved LDL-C. Despite the nearly complete independence of these two factors, there was also a linear relationship between the levels of CRP achieved after statin therapy and the risk of recurrent MI or coronary death. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The JUPITER trial, which randomly assigned patients with an LDL-C level below 130 mg/dL (3.4 mmol/L) and a CRP level of at least 2.0 mg/L to treatment with
         <a class="drug drug_general" data-topicid="10282" href="/z/d/drug information/10282.html" rel="external">
          rosuvastatin
         </a>
         20 mg daily or placebo and demonstrated better outcomes in the treated group, is discussed elsewhere. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         In the aggregate, these studies support the hypothesis that lowering serum CRP and LDL-C should be "dual" goals of statin therapy [
         <a href="#rid139">
          139
         </a>
         ]. Prospective randomized trials are necessary to evaluate this hypothesis.
        </p>
        <p class="headingAnchor" id="H16721169">
         <span class="h2">
          Other lipid-lowering agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among 18,144 patients in the IMPROVE IT-TIMI 22 trial who were stabilized after an ACS and randomized to
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         or ezetimibe/simvastatin, the addition of
         <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">
          ezetimibe
         </a>
         to a statin resulted in a 0.3 mg/L (16 percent) reduction in the median hs-CRP at one month and a 0.3 mg/L (14 percent) reduction over the study duration in comparison with simvastatin monotherapy [
         <a href="#rid140">
          140
         </a>
         ]. This effect of ezetimibe on hs-CRP translated to significantly more patients meeting both of the "dual" goals of LDL-C &lt;70 mg/dL and hs-CRP &lt;2 mg/L in the ezetimibe/simvastatin group in comparison with simvastatin alone (50 versus 29 percent). Patients achieving these "dual" goals had a lower rate of major cardiovascular events than patients meeting neither target (cardiovascular death, major coronary event, or stroke; 39 versus 28 percent; adjusted hazard ratio [HR] 0.73; 95% CI 0.66-0.81).
        </p>
        <p class="headingAnchor" id="H3457513099">
         <span class="h2">
          Anti-inflammatory agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapies that reduce inflammation should, in theory, reduce the adverse effects of atherosclerosis.
        </p>
        <p class="headingAnchor" id="H1378748266">
         <span class="h3">
          Monoclonal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the CANTOS trial, which enrolled 10,061 patients with a recent ACS and hs-CRP level ≥2 mg/L, patients were randomly assigned to receive one of three doses of
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         (50 mg, 150 mg, and 300 mg, administered subcutaneously every three months), a monoclonal antibody targeting the interleukin-1 beta, or to placebo [
         <a href="#rid141">
          141
         </a>
         ]. The primary efficacy end point was nonfatal MI, nonfatal stroke, or cardiovascular death. Compared with patients receiving placebo (4.50 events per 100 person-years), both the 150 mg (3.86 events per 100 person-years; HR 0.85; 95% CI 0.74-0.98) and 300 mg (3.90 events per 100 person-years; HR 0.86; 95% CI 0.75-0.99) doses of canakinumab resulted in a significant reduction of the primary end point. Canakinumab was associated with a significantly higher incidence of fatal infection than was placebo (0.31 versus 0.18 events per 100 person-years). Canakinumab had no effects on lipid levels, while it resulted in a dose-dependent reduction of CRP levels. In a prespecified secondary analysis, patients who achieved an on-treatment hs-CRP level &lt;2 mg/L had significant reductions in total mortality (adjusted HR 0.69; 95% CI 0.58-0.81), cardiovascular mortality, and major adverse cardiovascular events when compared with patients receiving placebo; no significant reductions in these outcomes were seen in patients whose on-treatment hs-CRP level remained ≥2 mg/L [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
         This is the first study to show that an anti-inflammatory drug with no effect on lipid levels improves the outcome of patients with ACS and systemic evidence of inflammation (elevated hs-CRP), therefore proving the inflammatory hypothesis of ACS [
         <a href="#rid141">
          141
         </a>
         ]. However, since the benefit of
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         on ischemic events was modest while it was associated with a higher risk of fatal infections, further studies are needed to confirm the safety and efficacy of this therapy, as well as to potentially identify other forms of anti-inflammatory treatments with a more favorable risk/benefit ratio. Canakinumab is not universally available for secondary prevention of ASCVD.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         does not reduce serum CRP in apparently healthy men [
         <a href="#rid143">
          143
         </a>
         ], serum CRP appears to influence the reduction in the relative risk of vascular disease induced by aspirin. In a report of healthy men from the Physicians' Health Study, the risk reduction with aspirin was much greater in those in the upper quartile of serum CRP compared with the lower quartile (56 versus 14 percent) [
         <a href="#rid47">
          47
         </a>
         ]. The clinical use of aspirin in primary and secondary CVD prevention are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">
          "Aspirin in the primary prevention of cardiovascular disease and cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with a variety of other medications, including thiazolidinediones and beta blockers, has been associated with lower levels of CRP, as has a diet rich in fiber and vegetables [
         <a href="#rid144">
          144-153
         </a>
         ]. Conversely, CRP levels appear to increase in women using menopausal hormone therapy [
         <a href="#rid154">
          154-156
         </a>
         ]. The clinical significance of these observations remains uncertain.
        </p>
        <p class="headingAnchor" id="H1018509040">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119659.html" rel="external">
          "Society guideline links: Assessment of cardiovascular risk"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenic mechanisms for ASCVD
         </strong>
         – Inflammation is a known factor in the development of atherosclerosis and subsequent atherosclerotic cardiovascular disease (ASCVD) events. The most extensively studied biomarker of inflammation in ASCVD is C-reactive protein (CRP). Despite a lack of specificity for the cause of inflammation, data from numerous epidemiologic studies have shown a significant association between elevated serum or plasma concentrations of CRP and the prevalence of underlying atherosclerosis, the risk of recurrent cardiovascular events among patients with established disease, and the incidence of first cardiovascular events among individuals at risk for atherosclerosis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Possible pathogenic role of CRP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of normal
         </strong>
         –
         <strong>
         </strong>
         While the ideal value that constitutes a high serum high-sensitivity CRP (hs-CRP; and increased cardiovascular risk) is not clearly defined, ranges articulated by the Centers for Disease Control and Prevention (CDC) and the American Heart Association (AHA) for the use of serum hs-CRP to estimate cardiovascular risk are employed when hs-CRP is measured for this purpose. There is no standardized CRP value that can be considered normal. However, individuals with values &lt;1 mg/L have been considered to be at lowest risk, with low-, average-, and high-risk values defined as &lt;1, 1 to 3, and &gt;3 mg/L. (See
         <a class="local">
          'Clinical context'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Observational studies
         </strong>
         –
         <strong>
         </strong>
         Several large population-based studies evaluating CRP in unselected asymptomatic populations have shown that, among apparently healthy individuals, the baseline level of CRP is associated with the long-term risk of a first myocardial infarction (MI), ischemic stroke, hypertension, peripheral vascular disease, sudden cardiac death, and all-cause mortality. While serum CRP does appear to act as an independent predictor of ASCVD in the general population, the predictive value added to that determined by screening for other coronary risk factors is small. (See
         <a class="local">
          'Association of CRP with cardiovascular risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role in screening for CVD risk
         </strong>
         – The use of hs-CRP to screen the general population for cardiovascular risk is controversial. While some experts recommend the routine measurement of hs-CRP at the time of cholesterol screening to be used as adjunctive data in the overall assessment of cardiovascular risk, we continue to prioritize the assessment of traditional risk factors and consider hs-CRP primarily for those with intermediate cardiovascular risk as determined using traditional risk factors and one or more of the available risk calculators. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Screening patients at low risk for ASCVD using hs-CRP has
         <strong>
          not
         </strong>
         been shown to change the current recommendations of lifestyle modifications in such individuals. Similarly, screening individuals at high risk for ASCVD with hs-CRP would
         <strong>
          not
         </strong>
         change current guideline-based management of established risk factors. Therefore, we do
         <strong>
          not
         </strong>
         recommend a strategy of routinely measuring hs-CRP in unselected populations to screen for ASCVD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients at intermediate risk for CVD using traditional risk factors and contemporary risk calculators (ie, 10 to 20 percent risk at 10 years) for whom a more definite estimate of cardiovascular risk might change their individual decision about whether or not to initiate statin therapy, we suggest a screening measurement of hs-CRP (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role in lipid-lowering therapy decision
         </strong>
         – The JUPITER trial suggests that the measurement of hs-CRP might help in the identification of asymptomatic patients at intermediate risk of cardiovascular events who may benefit from lipid-lowering treatment if CRP is &gt;2 mg/L. This information may be particularly useful in patients at intermediate risk who exhibit risk factors not incorporated in current risk stratification tools like a family history of early ischemic heart disease, obesity, and/or sedentary life. (See
         <a class="local">
          'Statins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role in anti-inflammatory treatment
         </strong>
         – The CANTOS trial suggests that patients with a history of MI and hs-CRP &gt;2 mg/L may benefit from an anti-inflammatory treatment. However, the role of anti-inflammatory treatment for patients post ACS remains to be determined. (See
         <a class="local">
          'Monoclonal antibodies'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nilsson J. CRP--marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005; 25:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113:2128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005; 111:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol 2004; 24:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepys MB, Hawkins PN, Kahan MC, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005; 97:e97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. PLoS One 2008; 3:e1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawlor DA, Harbord RM, Timpson NJ, et al. The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008; 3:e3011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005; 46:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand SS, Razak F, Yi Q, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24:1509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005; 165:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaskins AJ, Wilchesky M, Mumford SL, et al. Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study. Am J Epidemiol 2012; 175:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower JK, Lazo M, Juraschek SP, Selvin E. Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med 2012; 172:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Moll X, Zouridakis E, Cole D, Kaski JC. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J 2000; 21:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rifai N, Buring JE, Lee IM, et al. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002; 136:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah T, Newcombe P, Smeeth L, et al. Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circ Cardiovasc Genet 2010; 3:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 2005; 112:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung KC, Ryu S, Chang Y, et al. C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians. Eur Heart J 2014; 35:1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: A comparison between patients with and without liver dysfunction. Intensive Care Med 2006; 32:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. Am J Cardiol 2006; 98:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kervinen H, Palosuo T, Manninen V, et al. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J 2001; 141:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105:2595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattar N, Murray HM, Welsh P, et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6:e1000099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 2023; 401:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hingorani AD, Sofat R, Morris RW, et al. Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease? Eur Heart J 2012; 33:2258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sondermeijer BM, Boekholdt SM, Rana JS, et al. Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. Eur Heart J 2013; 34:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165:2063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006; 166:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165:2473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zebrack JS, Muhlestein JB, Horne BD, et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103:3062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000; 140:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004; 25:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98:2370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999; 34:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biasucci LM, Koenig W, Mair J, et al. How to use C-reactive protein in acute coronary care. Eur Heart J 2013; 34:3687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96:4204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makrygiannis SS, Ampartzidou OS, Zairis MN, et al. Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction. Am J Cardiol 2013; 111:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim P, Moutereau S, Simon T, et al. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]). Am J Cardiol 2013; 111:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harb TS, Zareba W, Moss AJ, et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002; 89:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zebrack JS, Anderson JL. Should C-reactive protein be measured routinely during acute myocardial infarction? Am J Med 2003; 115:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scirica BM, Cannon CP, Sabatine MS, et al. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem 2009; 55:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saleh N, Svane B, Jensen J, et al. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J 2005; 149:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002; 40:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011; 58:2630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalkman DN, Aquino M, Claessen BE, et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J 2018; 39:4101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosmidou I, Redfors B, Chen S, et al. C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial. Am Heart J 2019; 210:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JJ, Choi DJ, Yoon CH, et al. Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). Am J Cardiol 2014; 113:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000; 20:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bos MJ, Schipper CM, Koudstaal PJ, et al. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation 2006; 114:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33:2459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000; 102:2100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labarrere CA, Lee JB, Nelson DR, et al. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002; 360:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opotowsky AR, Valente AM, Alshawabkeh L, et al. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. Eur Heart J 2018; 39:3253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosca L. C-reactive protein--to screen or not to screen? N Engl J Med 2002; 347:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med 2002; 162:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laaksonen DE, Niskanen L, Nyyssönen K, et al. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J 2005; 26:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SC Jr, Milani RV, Arnett DK, et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004; 109:2613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Curry SJ, Krist AH, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JS, Evans CV, Johnson E, et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103:4188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter DH, Fichtlscherer S, Britten MB, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002; 40:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol &lt;70 mg/dl and C-reactive protein &lt;2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005; 45:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018; 391:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37:2036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45:1925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42:1757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 2002; 112:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 2004; 117:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King DE, Egan BM, Woolson RF, et al. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch Intern Med 2007; 167:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao X, Bermudez OI, Tucker KL. Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. J Nutr 2004; 134:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balducci S, Zanuso S, Nicolucci A, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010; 20:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer RD, Pradhan AD, Lewis CE, et al. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 2005; 93:1108.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1484 Version 56.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7046585" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The phenomenon of the acute phase response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12551878" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18971492" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genetically elevated C-reactive protein and ischemic vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12490960" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Inflammation in atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16055753" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : CRP--marker or maker of cardiovascular disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651484" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11448405" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Association of C-reactive protein with markers of prevalent atherosclerotic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238260" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15774855" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Activation of inflammation and coagulation after infusion of C-reactive protein in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12186793" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11056086" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Direct proinflammatory effect of C-reactive protein on human endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11382718" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15795363" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15044210" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : C-reactive protein does not directly induce tissue factor in human monocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802626" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16254214" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18167554" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18714384" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567438" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12551853" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical application of C-reactive protein for cardiovascular disease detection and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238291" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16053959" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Race and gender differences in C-reactive protein levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15205215" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : C-reactive protein as a screening test for cardiovascular risk in a multiethnic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031795" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238295" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15668370" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Fluctuating inflammatory markers in patients with stable ischemic heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22306563" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22945505" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Within-person variability in high-sensitivity C-reactive protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10988012" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15602020" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Inflammatory markers and the risk of coronary heart disease in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727541" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10733371" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12432042" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983251" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11926788" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Is C-reactive protein specific for vascular disease in women?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12190368" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876875" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16116058" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24569028" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16799774" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : C-reactive protein concentrations during bacteraemia: A comparison between patients with and without liver dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9987089" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17056347" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11275923" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Joint effects of C-reactive protein and other risk factors on acute coronary events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11282915" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15023871" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15197153" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9077376" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9490235" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9610529" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892589" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10988010" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22910756" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12045163" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14665655" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : C-reactive protein and the risk of developing hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19554082" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17283264" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36893777" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22766581" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070788" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17299196" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23449857" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031199" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19805771" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23034020" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : C-reactive protein, fibrinogen, and cardiovascular disease prediction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16216995" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16832001" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314543" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11849862" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11425769" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9040576" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10925350" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7845427" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738637" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15033252" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : C-reactive protein elevation and disease activity in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17372173" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15381646" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9832480" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2296885" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Elevation of C-reactive protein in "active" coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7880233" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577559" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Enhanced inflammatory response in patients with preinfarction unstable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8790019" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Elevated levels of interleukin-6 in unstable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24204013" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : How to use C-reactive protein in acute coronary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9626820" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9416883" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11036119" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807457" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027805" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12651034" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16516078" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23040593" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23062316" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792346" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15261928" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14693328" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Should C-reactive protein be measured routinely during acute myocardial infarction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19074516" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15894971" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11524391" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11914246" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11693760" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12392824" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22152948" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30358832" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30738244" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16129801" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : C-reactive protein in heart failure: prognostic value and the effect of valsartan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16183690" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24315115" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435339" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10764672" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015791" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10229731" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : C-reactive protein and outcome after ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283392" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : C-reactive protein in ischemic stroke: an independent prognostic factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12364738" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044427" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12433514" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30010900" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12432050" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : C-reactive protein--to screen or not to screen?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11966336" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821003" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15173043" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329177" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18997196" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29998297" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29998301" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19812802" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11306519" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12234946" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10411845" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11434828" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10933353" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10459915" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Inhibition of proinflammatory cytokine production by pravastatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14976045" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337732" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15635109" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : C-reactive protein levels and outcomes after statin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11430324" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11738308" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665489" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Relation of inflammation and benefit of statins after percutaneous coronary interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12103255" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16847150" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15893181" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol&lt;70 mg/dl and C-reactive protein&lt;2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26330412" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28845751" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29146124" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11419884" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12163427" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15963388" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14642684" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239709" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11893365" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876093" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15380496" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17353499" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051846" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19695853" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10449693" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10449692" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Hormone replacement therapy and increased plasma concentration of C-reactive protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15968396" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
